Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30

$0.84+0.01 (+1.41%)

Close on Nov 13, 2026Market cap $289.76MP/E –Yield 0.00%

Allogene Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Allogene Therapeutics's price to sales ratio was 14.7× on Jan 31, 2023, against 42.4× a year earlier.

Period	Period end	Value	Change (pts)
2023	Jan 31, 2023	14.7×	+2.7
2022	Dec 30, 2022	12.0×	−43.3
2021	Dec 31, 2021	55.3×	–

Parsed from the XBRL in Allogene Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ALLO.

Revenue growth-100.0% · median -41.1%

Advertisement
300 × 250

See a number that looks wrong?